ALPHA-MSH THERAPIES FOR TREATMENT OF AUTOIMMUNE DISEASE

• US 20110059891A1
• Filed: 10/04/2010
• Published: 03/10/2011
• Est. Priority Date: 10/18/2006
• Status: Active Grant

• Current Assignee: Staley A. Brod
• Original Assignee: Staley A. Brod
• Inventors: Brod, Staley A.
• Granted Patent: US 8,758,770 B2
• Time in Patent Office: Days
• US Class Current: 514/10.8
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 38/21 Interferons [IFN]
• CPC Class Codes: A61K 38/34 Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 5/14 of the thyroid hormones, e.g. T3, T4

Abstract

Methods and compositions for the enteral treatment of autoimmune disease such a multiple sclerosis with polypeptide therapeutics. Enteral therapeutics comprise monomeric alpha-MSH polypeptides such as ACTH. Therapeutic formulations of the invention may be used to reduce the incidence or severity of autoimmune disease. For instance methods for the oral treatment of multiple sclerosis with alpha-MSH and ACTH are described.

Claims

1. A method for treating or delaying the onset of an autoimmune disease in a human subject comprising orally administering to the subject an effective dose of ACTH.

5. The method of claim 1, wherein the ACTH is blocked at the amino terminus, the carboxy terminus or both.

6. The method of claim 5, wherein the ACTH is acetylated at the amino terminus and amidated at the carboxy terminus.

11. The method of claim 1, wherein the ACTH is administered in a liquid form.

12. The method of claim 1, wherein the ACTH is administered in a solid form.

13. The method of claim 1, wherein the disease is rheumatoid arthritis, psoriasis, type 1 diabetes, systemic lupus erythematosus (SLE), transplant rejection, autoimmune thyroid disease (Hashimoto'"'"'s disease), sarcoidosis, scleroderma, granulomatous vasculitis, Crohn'"'"'s disease, ulcerative colitis, Sjogren'"'"'s disease, ankylosing spondylitis, polymyositis dermatomyositis, polyarteritis nodosa, immunologically mediated blistering skin diseases, Behç

et'"'"'s syndrome, multiple sclerosis, systemic sclerosis, Goodpasture'"'"'s disease or immune mediated glomerulonephritis.

14. The method of claim 13, wherein the disease is multiple sclerosis.

2-4. -4. (canceled)

7-10. -10. (canceled)

15-31. -31. (canceled)